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SAT0047 PREDICTING MAINTENANCE OF RESPONSE BASED ON DISEASE CHARACTERISTICS AND EARLY CLINICAL RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS UPON WITHDRAWAL OF ADALIMUMAB
Background: Some patients (pts) with rheumatoid arthritis (RA) achieve low disease activity (LDA) after treatment with adalimumab (ADA) plus methotrexate (MTX) and can maintain LDA after ADA withdrawal 1 . However, others experience a flare in disease activity. The factors associated with loss or maintenance of response are not understood. Objectives: To identify pt disease characteristics and early clinical responses, which predict maintenance of LDA upon ADA withdrawal in individual RA pts. Methods: Data from the OPTIMA trial were used in this post hoc analysis. In period 1 (P1), pts were treated for 26 weeks (wks) with ADA+MTX or placebo (PBO) +MTX. Pts on ADA+MTX who achieved DAS28-CRP <3.2 at wks 22 and 26 (responders) were randomized to ADA withdrawal, or ADA+MTX continuation up to Wk 78. Responders to PBO+MTX in P1 continued on PBO+MTX up to Wk 78 (PBO continuation). Data from the ADA withdrawal arm were used to predict LDA at Wk 78 by DAS28-CRP (≤3.2) or SDAI (≤11). Potential factors including baseline (BL) disease characteristics and Wk 26 responses, including DAS28-CRP, SDAI, ACR score components, modified total sharp score (mTSS) and joint space narrowing score (JSN), were screened by the LASSO method 2 , which performs variable selection by penalizing unduly complicated models, with/without incorporating the speed of DAS28-CRP or SDAI response as an individual predictor. Logistic regression on the LASSO-selected factors yielded coefficients used to derive individual scoring equations and prediction scores for Wk 78 outcomes (fig footnote). Prediction score cutoffs were established by the regression tree method 3 . The results were validated in data from the PBO continuation arm. Results: For the prediction of DAS28-CRP LDA at Wk 78, BL physician global assessment (PhGA) and health-assessment questionnaire-disability index (HAQ-DI), and Wk 26 DAS28-CRP, HAQ-DI, JSN and CRP were selected by LASSO, and used to calculate the prediction score. Including speed of response did not affect the predictors chosen. Out of 9 pts predicted not to have DAS28-CRP LDA at Wk 78, 0 had LDA (NPV=100%) (fig 1) . Out of 66 pts predicted to have DAS28-CRP LDA at Wk 78, 63 predictions were correct (PPV=96.5%). Results were comparable for most cutoff categories in the validation arm (PPV=82%); however, no pts were predicted to have a non-response at Wk 78. For the prediction of SDAI LDA at Wk 78, the NPV was 86% (1/7 predictions incorrect); PPV was 95% (39/41 predictions correct); in the validation arm, the PPV was 82%. Conclusions: DAS28-CRP LDA at 78 wks could be individually predicted for up to 63% pts in OPTIMA who withdrew ADA/continued PBO+MTX with 96.5% accuracy, based on demographics and clinical outcomes at 6 months. This instrument could help identify pts who may be able to maintain LDA upon ADA withdrawal. Background: There is today a paucity of prospective studies to describe the natural longitudinal history of anti-ccp positive individuals developing RA or not developing RA. Further no study to investigate the detailed ACPA reactivities in such a setting is currently available. Methods: Individuals at risk of developing RA were included in a cohort at Karolinska University Hospital, Stockholm. Examinations of peripheral joints was repeated at one year follow-up visit or at any time the patients experienced worsening of their symptoms. Peripheral blood samples were available at inclusion (n=70). Serum was run on a microarray based on the ImmuoCAP ISAC system testing for ACPA reactivities toward 13 different citrullinated peptides (fillagrin, fibrinogen, alpha-enolase, vimentin, histone) (1). Results: Individuals referred from primary care with musculoskeletal complaints and positive anti-ccp test were systematically investigated as part of routine care at our rheumatology clinic. Individuals lacking self-reported history of suspect arthritis, clinical arthritis according to rheumatologist and signs of synovitis on ultrasound examination were included in a clinical Risk-RA program with life-style coaching and personalized information on the risk of developing RA. Seventy individuals, with a mean age of 48 years (SD 15) and 86% females, were included in the program. Twenty (29%) individuals developed arthritis during a medium follow up time of 7 months (range 1-25 months). Number of ACPA reactivities at baseline was significant higher among those developing (in mean 6 reactivities) as compared to those not developing arthritis (in mean 4 reactivities). A increased proportion of individuals were showing reactivity towards citrullinated (cit) vimentin (vim) 60-75, fibrinogen (fib) 573 and enolase (eno) (CEP-1) among those developing arthritis (80% for anti-cit-vim 45% for anti-cit-fib and 60% for anti-cit eno) as compared to those not developing arthritis (41% for anti-cit-vim, 30% for anti-cit-fib and 52% for anti-cit-eno). Increased level of anti-cit-vim and anti-cit-eno antibodies was also observed at inclusion for those individuals developing arthritis as compared to those not developing arthritis.
Conclusions:
We describe here the pattern of ACPA reactivities in anti-CCP positive individuals with non-specific musculoskeletal symptoms at risk of developing RA and without clinical and ultrasonograph signs of synovitis and report that 30% of these patients will develop arthritis during a short follow-up. Number, frequency and titers of specific ACPA reactivities appear to be enriched already at inclusion among those patients that developed arthritis during follow-up. 
